GLP-1 Weight-Loss Medications: Benefits, Side Effects and Risks (Complete 2026 US Doctor’s Guide — FDA + NIDDK + NIH)

Short answer: GLP-1 weight-loss medications are a class of FDA-approved injectable drugs that mimic glucagon-like peptide-1, a natural gut hormone released after eating. In US adults, they typically produce 15–22% total body weight loss over 68–72 weeks when combined with reduced calorie intake and increased physical activity (per NIDDK, STEP, and SURMOUNT trials). FDA-approved GLP-1 weight-loss medications for chronic weight management include semaglutide (Wegovy), tirzepatide (Zepbound) — a dual GIP/GLP-1 receptor agonist — and liraglutide (Saxenda). Common side effects are gastrointestinal (nausea, vomiting, constipation, diarrhoea); serious but rare risks include pancreatitis, gallbladder disease, and a boxed warning for medullary thyroid carcinoma (MTC) in patients with personal or family history or MEN-2 syndrome.

Table of Contents

1. What Are GLP-1 Weight-Loss Medications?
2. How They Work — Mechanism of Action
3. FDA-Approved GLP-1 Weight-Loss Medications in the US
4. Who Is Eligible — BMI Criteria
5. Benefits — Weight Loss, Metabolic, Cardiovascular
6. Common Side Effects
7. Serious Risks and Boxed Warnings
8. Contraindications
9. Dose Escalation Schedule
10. Costs and US Insurance Coverage
11. Lifestyle, Diet, and Exercise Pairing
12. What Happens When You Stop
13. Monitoring Plan
14. FAQs
15. References

1. What Are GLP-1 Weight-Loss Medications?

GLP-1 weight-loss medications are a group of prescription injectable drugs originally developed for type 2 diabetes and later approved for chronic weight management in adults with obesity. The US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) lists them as the most effective pharmacologic category for sustained weight loss when combined with a reduced-calorie diet and regular physical activity. In the United States, more than 42% of adults have obesity (CDC NHANES 2023), and GLP-1 weight-loss medications have become a central tool in American obesity care.

2. How They Work — Mechanism of Action

Native glucagon-like peptide-1 is secreted by intestinal L-cells after a meal. It binds the GLP-1 receptor (GLP-1R) on pancreatic β-cells, the brain (arcuate nucleus of the hypothalamus, nucleus tractus solitarius), stomach, and other tissues to:

• Stimulate glucose-dependent insulin secretion
• Suppress glucagon
• Slow gastric emptying
• Reduce appetite and increase satiety through central CNS pathways
• Modestly lower systolic blood pressure and improve lipid profile

Tirzepatide is a dual GIP/GLP-1 receptor co-agonist, adding effects on glucose-dependent insulinotropic polypeptide (GIP) that enhance both weight loss and glycaemic control. This dual action is why Zepbound produces greater weight loss than Wegovy in head-to-head data (SURMOUNT-5, 2024).

3. FDA-Approved GLP-1 Weight-Loss Medications in the US

As of 2026, these are the specific FDA-approved GLP-1 weight-loss medications for chronic weight management:

• Semaglutide — Wegovy® (Novo Nordisk) — once-weekly subcutaneous injection, 0.25 → 2.4 mg; approved June 2021
• Tirzepatide — Zepbound® (Eli Lilly) — once-weekly subcutaneous injection, 2.5 → 15 mg; approved November 2023
• Liraglutide — Saxenda® (Novo Nordisk) — once-daily subcutaneous injection, 0.6 → 3.0 mg; approved 2014; now generic in some markets

Note: Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved only for type 2 diabetes, not for weight loss, though they contain the same active molecule as Wegovy and Zepbound. Prescribing them off-label for weight loss is a different clinical and insurance situation.

4. Who Is Eligible — BMI Criteria

Per FDA labeling and NIDDK guidance, GLP-1 weight-loss medications are indicated for adults with:

• BMI ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease

Wegovy is also approved for adolescents aged ≥12 with obesity. Zepbound was additionally approved in late 2024 for moderate-to-severe obstructive sleep apnoea in adults with obesity.

5. Benefits — Weight Loss, Metabolic, Cardiovascular

Average weight loss over 68–72 weeks on GLP-1 weight-loss medications in US adults:

• Semaglutide (Wegovy) 2.4 mg weekly — ~15% total body weight (STEP-1, N Engl J Med 2021)
• Tirzepatide (Zepbound) 15 mg weekly — ~22.5% total body weight (SURMOUNT-1, N Engl J Med 2022)
• Liraglutide (Saxenda) 3.0 mg daily — ~8% total body weight (SCALE)

Beyond weight, documented benefits include:

• SELECT trial (NEJM 2023): Wegovy reduced major adverse cardiovascular events (MACE) by 20% in non-diabetic adults with CVD and overweight/obesity
• Improved HbA1c, blood pressure, triglycerides, NAFLD / MASLD
• FLOW trial (2024): slowed progression of diabetic kidney disease
• Lower rates of obstructive sleep apnoea (SURMOUNT-OSA)
• Reduced symptoms of HFpEF (STEP-HFpEF)

6. Common Side Effects

Up to 70% of US patients on GLP-1 weight-loss medications experience at least one of these during dose escalation (usually transient):

• Nausea (most common, ~44%)
• Vomiting (~24%)
• Diarrhoea (~30%)
• Constipation (~24%)
• Abdominal pain
• Dyspepsia, gastro-oesophageal reflux
• Fatigue
• Headache
• Injection-site reaction
• Hair thinning (usually transient, linked to rapid weight loss)

Side effects are reduced by slow dose titration (every 4 weeks per package insert), smaller meals, lower-fat foods, and adequate hydration.

7. Serious Risks and Boxed Warnings

Though uncommon, these risks are listed in the FDA prescribing information:

• Acute pancreatitis — stop drug immediately for persistent severe abdominal pain radiating to the back
• Gallbladder disease — cholelithiasis, cholecystitis, rate up to 2–3%
• Boxed warning: Medullary thyroid carcinoma (MTC) — rodent data show C-cell tumors; human relevance uncertain. Contraindicated in anyone with personal or family history of MTC or MEN-2 syndrome.
• Hypoglycaemia — rare when used without insulin or sulfonylurea
• Acute kidney injury — usually in setting of volume depletion from vomiting/diarrhoea
• Diabetic retinopathy worsening in rapid HbA1c drop
• Possible increased risk of gastroparesis and ileus (post-marketing)
• Suicidal ideation signals in post-marketing surveillance — EMA and FDA 2024 reviews found no causal link, but monitoring continues
• Pulmonary aspiration during anaesthesia — American Society of Anesthesiologists advises holding dose before elective surgery

8. Contraindications

Do NOT use GLP-1 weight-loss medications if:

• Personal or family history of medullary thyroid carcinoma or MEN-2
• Pregnancy, planned pregnancy within 2 months, or breastfeeding
• Prior serious hypersensitivity to the molecule
• History of severe gastroparesis
• History of recurrent pancreatitis (relative contraindication)

9. Dose Escalation Schedule

Wegovy: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, each dose for 4 weeks.
Zepbound: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, each dose for 4 weeks.
Saxenda: 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg daily, one week each.
Pause or step back if side effects are severe.

10. Costs and US Insurance Coverage

US list price (2026):

• Wegovy: ~US$1,350/month list; often US$500–700 with manufacturer savings card
• Zepbound: ~US$1,060/month list; US$550 self-pay vial program (Lilly Direct)
• Saxenda: ~US$1,350/month list

Coverage varies widely:

• Many commercial insurance plans cover one or both after prior authorization and documented BMI/comorbidity
• Medicare Part D traditionally does NOT cover anti-obesity drugs under the Medicare Modernization Act; however, Medicare Part D covers Wegovy for patients with established cardiovascular disease (post-SELECT, March 2024), and Zepbound for moderate-to-severe sleep apnoea with obesity (2024).
• Medicaid coverage varies by state — ~20 states cover GLP-1 weight-loss medications for obesity
• Patient-assistance programs: NovoCare and Lilly Cares
• FDA ended its compounded semaglutide shortage designation in 2024; compounded versions are now rarely a legal option

11. Lifestyle, Diet, and Exercise Pairing

Per NIDDK, drug therapy must be paired with:

• Calorie deficit of 500–750 kcal/day via Mediterranean, DASH, or similar healthy eating pattern
• ≥150 minutes/week moderate aerobic activity
• Resistance training at least 2 days/week — critical to protect lean body mass
• Protein intake 1.2–1.6 g/kg of ideal body weight/day
• Behavioural counselling (individual or group)

Related reading: See GLP-1 medications and muscle loss for how to preserve lean mass, what happens when you stop taking semaglutide, and can you regain weight after stopping tirzepatide. For affordable eating patterns to pair with therapy, see how to eat a healthy diet on a tight budget and affordable high-protein foods for families.

12. What Happens When You Stop

Discontinuation typically returns appetite and gastric motility to baseline within 4–8 weeks. The STEP-4 and SURMOUNT-4 trials showed ~65–70% weight regain within 1 year of stopping, which is why most guidelines treat obesity as a chronic disease requiring ongoing therapy. (See the companion articles linked above for a deep dive.)

13. Monitoring Plan

• Baseline: weight, BMI, waist circumference, HbA1c, lipids, LFTs, creatinine, pregnancy test if applicable, review of family MTC history
• Every 4 weeks during titration: weight, side-effect check, dose adjustment
• Every 3 months after target dose: weight, blood pressure, HbA1c, labs if indicated
• Annual: review of total weight loss, cardiometabolic benefits, DEXA or BIA if lean-mass concern

14. External Video Resource

NIDDK: Prescription Medications for Weight Loss (YouTube)

15. FAQs

Q1. Are GLP-1 weight-loss medications safe for long-term use?
Current data up to 4 years (SELECT, SURMOUNT extensions) show sustained safety when titrated and monitored by a clinician.

Q2. Does insurance cover Wegovy or Zepbound in the US?
Many commercial plans cover with prior authorization; Medicare covers in specific cardiovascular or sleep apnoea indications; Medicaid varies by state.

Q3. Can I take compounded semaglutide instead?
The FDA ended the official shortage in 2024; compounded versions carry safety, dosing accuracy, and purity concerns. Use only an FDA-approved product under physician care.

Q4. Will I regain weight when I stop?
Most patients regain a significant portion within a year unless they maintain structured lifestyle change. Obesity is chronic.

Q5. Can GLP-1s help type 1 diabetes?
Not FDA-approved for T1DM; some research is exploring adjunctive use in adults with T1DM and obesity.

Q6. Do GLP-1 medications cause thyroid cancer in humans?
Rodent studies showed C-cell tumors; human data are not conclusive but the FDA retains the boxed warning. Avoid in anyone with MTC or MEN-2 history.

Q7. Is Ozempic the same as Wegovy?
Both are semaglutide, but Ozempic is approved for type 2 diabetes and dosed to 2.0 mg; Wegovy is approved for weight management and dosed to 2.4 mg. Different labels, pricing, and insurance pathways.

16. When to See a Doctor Urgently

Call your clinician or seek care at a US emergency department (dial 911) for severe abdominal pain radiating to the back, persistent vomiting with inability to keep fluids down, severe dehydration, right-upper-quadrant pain with fever (cholecystitis), vision changes in a diabetic patient, or any sign of a severe allergic reaction.

17. Conclusion

GLP-1 weight-loss medications represent the most effective pharmacologic class for chronic weight management ever brought to the US market, with FDA-approved options producing 15–22% total body weight loss and cardiovascular, kidney, sleep, and metabolic benefits. The side-effect profile is predominantly gastrointestinal and manageable; serious risks are rare but real. In the United States, insurance coverage is improving, and NIDDK provides patient-friendly guidance to help eligible adults access these therapies safely alongside sustainable diet, exercise, and behavioural change. These medications are not shortcuts — they are chronic disease treatments that work best as part of a structured, physician-supervised plan.

18. References

1. US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription Medications to Treat Overweight & Obesity, 2024.
2. US FDA. Prescribing information: Wegovy, Zepbound, Saxenda, 2024–2025.
3. Wilding JPH et al. STEP-1. N Engl J Med 2021.
4. Jastreboff AM et al. SURMOUNT-1. N Engl J Med 2022.
5. Lincoff AM et al. SELECT. N Engl J Med 2023.
6. CDC. Adult Obesity Facts, 2024.
7. Perkovic V et al. FLOW. N Engl J Med 2024.
8. Kosiborod MN et al. STEP-HFpEF. N Engl J Med 2023.

Medical Disclaimer: This article is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any medical condition or before making any decisions related to your health. Do not disregard or delay seeking professional advice based on information provided in this article.